We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
Read MoreHide Full Article
Henry Schein’s (HSIC - Free Report) dental laboratory business — Zahn Dental — recently entered into an exclusive agreement to distribute the global dental manufacturing company, Myerson’s newly launched Trusana Premium Denture System. Comprising three products — the Trusana Premium 3D Tooth Resin, Trusana Premium 3D Denture Base Resin and Trusana Bond Denture Adhesive — the system works together to create a premium denture with optimal physical properties and esthetics for dental laboratories.
Henry Schein’s Zahn Dental is focused on delivering products and services that help foster the adoption of digital solutions in dentistry, specifically among lab technicians. Zahn Dental's relationship with Myerson will help Henry Schein strengthen its digital dentistry offerings.
News in Detail
Zahn Dental’s comprehensive offering of industry-leading innovative products, breakthrough technologies, value-added services and technical support makes it a total solution provider. The business is a leading distributor of CAD/CAM equipment, digital materials, removable prosthetic teeth and traditional core supplies to dental laboratories in North America. The addition of Myerson’s complete digital denture system further strengthens Zahn Dental’s portfolio of dental laboratory solutions that help improve its customers’ production processes and enhance patient outcomes.
Image Source: Zacks Investment Research
Created by a team of scientists and clinicians from around the world, Trusana’s patented chemistry delivers an unfilled polymer with high-impact strength and toughness. The flexural strength, modulus, fracture toughness and wear resistance of this polymer are well beyond that of conventional 3D-printed denture materials. Trusana resins won a RadTech/UVA Emerging Technology award for additive manufacturing in 2020.
The Trusana Premium Denture System’s innovative science and technology help dental laboratories produce final digital dentures that maintain strength and the characteristics of a traditional denture. Together, Trusana Premium 3D printing resins result in a high-quality product while helping save time, money and materials.
Industry Prospects
Per a Research report, the global digital dentistry market was valued at $4.2 billion in 2021 and is expected to witness a CAGR of 13.1% by 2032.
Prospects of Digital Dentistry
With dentistry undergoing a significant transition to integrate high-tech digital workflow systems into the dental practice, HSIC remains a favorable choice for customers who are seeking an integrated digital clinical workflow. Earlier in 2023, North American sales of digital equipment comprising 2D and 3D digital imaging, mills and intra-oral scanners returned to growth. However, sales were lower in the third quarter, which reflected a declining average selling price for intra-oral scanners as a result of new products introduced late last year.
The company closed one of its larger transactions this year with Biotech Dental, adding its comprehensive, integrated suite of planning and diagnostic software to Henry Schein’s portfolio of digital dental solutions and fast-growing the portfolio of implants and clear aligners. Within Henry Schein’s technology and value-added service businesses, the largest contributor’s, Henry Schein One, growth continues to be driven by practice management software solutions and cloud-based solutions — Dentrix Ascend and Dentally — which provide the opportunity for dental practitioners to integrate their clinical workflow.
Price Performance
In the past six months, HSIC shares have decreased 8.1% against the industry’s rise of 1%.
Zacks Rank and Key Picks
Henry Schein currently carries a Zacks Rank #4 (Sell).
Haemonetics’ stock has decreased 1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry’s decline of 3.3%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry’s decline of 4.7%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
Henry Schein’s (HSIC - Free Report) dental laboratory business — Zahn Dental — recently entered into an exclusive agreement to distribute the global dental manufacturing company, Myerson’s newly launched Trusana Premium Denture System. Comprising three products — the Trusana Premium 3D Tooth Resin, Trusana Premium 3D Denture Base Resin and Trusana Bond Denture Adhesive — the system works together to create a premium denture with optimal physical properties and esthetics for dental laboratories.
Henry Schein’s Zahn Dental is focused on delivering products and services that help foster the adoption of digital solutions in dentistry, specifically among lab technicians. Zahn Dental's relationship with Myerson will help Henry Schein strengthen its digital dentistry offerings.
News in Detail
Zahn Dental’s comprehensive offering of industry-leading innovative products, breakthrough technologies, value-added services and technical support makes it a total solution provider. The business is a leading distributor of CAD/CAM equipment, digital materials, removable prosthetic teeth and traditional core supplies to dental laboratories in North America. The addition of Myerson’s complete digital denture system further strengthens Zahn Dental’s portfolio of dental laboratory solutions that help improve its customers’ production processes and enhance patient outcomes.
Image Source: Zacks Investment Research
Created by a team of scientists and clinicians from around the world, Trusana’s patented chemistry delivers an unfilled polymer with high-impact strength and toughness. The flexural strength, modulus, fracture toughness and wear resistance of this polymer are well beyond that of conventional 3D-printed denture materials. Trusana resins won a RadTech/UVA Emerging Technology award for additive manufacturing in 2020.
The Trusana Premium Denture System’s innovative science and technology help dental laboratories produce final digital dentures that maintain strength and the characteristics of a traditional denture. Together, Trusana Premium 3D printing resins result in a high-quality product while helping save time, money and materials.
Industry Prospects
Per a Research report, the global digital dentistry market was valued at $4.2 billion in 2021 and is expected to witness a CAGR of 13.1% by 2032.
Prospects of Digital Dentistry
With dentistry undergoing a significant transition to integrate high-tech digital workflow systems into the dental practice, HSIC remains a favorable choice for customers who are seeking an integrated digital clinical workflow. Earlier in 2023, North American sales of digital equipment comprising 2D and 3D digital imaging, mills and intra-oral scanners returned to growth. However, sales were lower in the third quarter, which reflected a declining average selling price for intra-oral scanners as a result of new products introduced late last year.
The company closed one of its larger transactions this year with Biotech Dental, adding its comprehensive, integrated suite of planning and diagnostic software to Henry Schein’s portfolio of digital dental solutions and fast-growing the portfolio of implants and clear aligners. Within Henry Schein’s technology and value-added service businesses, the largest contributor’s, Henry Schein One, growth continues to be driven by practice management software solutions and cloud-based solutions — Dentrix Ascend and Dentally — which provide the opportunity for dental practitioners to integrate their clinical workflow.
Price Performance
In the past six months, HSIC shares have decreased 8.1% against the industry’s rise of 1%.
Zacks Rank and Key Picks
Henry Schein currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DexCom (DXCM - Free Report) . Haemonetics and DexCom each presently carry a Zacks Rank #2 (Buy), and Insulet sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has decreased 1% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.89 in 2023 and $4.07 to $4.15 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.91 in the past 30 days. Shares of the company have dropped 36.5% in the past year compared with the industry’s decline of 3.3%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.39 to $1.43 in the past 30 days. Shares of the company have increased 0.1% in the past year compared with the industry’s decline of 4.7%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.